We read with great interest the article by Albrecht et al.1 regarding the long-term clinical safety of Clindamycin and Rifampicin combination for the treatment of Hidradenitis Suppurativa (HS). The authors discuss carefully whether Clindamycin and Rifampicin could be safely continued beyond a 10 week course, analyzing long term toxicity of these drugs. This article is protected by copyright. All rights reserved.
Long-term clinical safety of Clindamycin and Rifampicin combination for the treatment of Hidradenitis Suppurativa: strategy to reduce side effects, improving patients' compliance / Marasca, C; Masarà, A; Annunziata, M C; Bettoli, V; Luciano, M A; Fabbrocini, G. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - 180:4(2019), pp. 949-949. [10.1111/bjd.17423]
Long-term clinical safety of Clindamycin and Rifampicin combination for the treatment of Hidradenitis Suppurativa: strategy to reduce side effects, improving patients' compliance
Marasca, C;Masarà, A;Annunziata, M C;Fabbrocini, G
2019
Abstract
We read with great interest the article by Albrecht et al.1 regarding the long-term clinical safety of Clindamycin and Rifampicin combination for the treatment of Hidradenitis Suppurativa (HS). The authors discuss carefully whether Clindamycin and Rifampicin could be safely continued beyond a 10 week course, analyzing long term toxicity of these drugs. This article is protected by copyright. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
